Literature DB >> 9399495

Antigenic variation of core, NS3, and NS5 proteins among genotypes of hepatitis C virus.

J A Neville1, L E Prescott, V Bhattacherjee, N Adams, I Pike, B Rodgers, A El-Zayadi, S Hamid, G M Dusheiko, A A Saeed, G H Haydon, P Simmonds.   

Abstract

Assays that detect antibody to hepatitis C virus (HCV) are used to screen blood donors and patients with hepatitis. Current enzyme-linked immunosorbent assay (ELISA)-based methods are invariably based upon antigens from expressed recombinant proteins or oligopeptides from HCV type 1. Some HCV antigens used in screening assays are coded by regions of the HCV genome that show extensive variability; therefore, HCV type 1-based assays may be less effective for the detection of antibody elicited by infection with other genotypes. In this study, we have measured antibody reactivity of sera from 110 hepatitis C patients infected with type 1b, 3a, or 4a to genotype-specific and cross-reactive epitopes present in recombinant proteins from HCV genotypes 1b (core, NS3, and NS5), 3a (NS3, NS5), and 4a (core, NS3), corresponding to those used in current third-generation screening ELISAs. By comparing the serological reactivities of sera to type-homologous and type-heterologous antigens, we detected a significant type-specific component to the reactivity to NS3 (61 to 77% of the total reactivity) and NS5 (60% of the total reactivity). Furthermore, despite the similarities in the amino acid sequences of the core antigens of type 1b and type 4a, we also found significantly greater reactivity to type-homologous antigens, with approximately 25% of reactivity being type specific. These findings are consistent with previous findings of fivefold weaker reactivity of sera from HCV type 2- and HCV type 3-infected blood donors in the currently used third-generation ELISAs and suggest that these assays are suboptimal for screening populations in which the predominant genotype is not type 1.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9399495      PMCID: PMC230123          DOI: 10.1128/jcm.35.12.3062-3070.1997

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  28 in total

1.  Two distinct subtypes of hepatitis C virus defined by antibodies directed to the putative core protein.

Authors:  A Machida; H Ohnuma; F Tsuda; E Munekata; T Tanaka; Y Akahane; H Okamoto; S Mishiro
Journal:  Hepatology       Date:  1992-10       Impact factor: 17.425

2.  Complete nucleotide sequence of a type 4 hepatitis C virus variant, the predominant genotype in the Middle East.

Authors:  R W Chamberlain; N Adams; A A Saeed; P Simmonds; R M Elliott
Journal:  J Gen Virol       Date:  1997-06       Impact factor: 3.891

3.  Mapping of serotype-specific, immunodominant epitopes in the NS-4 region of hepatitis C virus (HCV): use of type-specific peptides to serologically differentiate infections with HCV types 1, 2, and 3.

Authors:  P Simmonds; K A Rose; S Graham; S W Chan; F McOmish; B C Dow; E A Follett; P L Yap; H Marsden
Journal:  J Clin Microbiol       Date:  1993-06       Impact factor: 5.948

4.  Genetic organization and diversity of the hepatitis C virus.

Authors:  Q L Choo; K H Richman; J H Han; K Berger; C Lee; C Dong; C Gallegos; D Coit; R Medina-Selby; P J Barr
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-15       Impact factor: 11.205

5.  Patterns of serological markers in transfusion-transmitted hepatitis C virus infection using second-generation HCV assays.

Authors:  P N Lelie; H T Cuypers; H W Reesink; C L van der Poel; I Winkel; E Bakker; P J van Exel-Oehlers; D Vallari; J P Allain; L Mimms
Journal:  J Med Virol       Date:  1992-07       Impact factor: 2.327

6.  Anti-hepatitis C virus (anti-HCV) seroconversion in patients undergoing hemodialysis: comparison of second- and third-generation anti-HCV assays.

Authors:  A M Couroucé; N Le Marrec; A Girault; S Ducamp; N Simon
Journal:  Transfusion       Date:  1994-09       Impact factor: 3.157

7.  Frequent reinfection and reactivation of hepatitis C virus genotypes in multitransfused hemophiliacs.

Authors:  L M Jarvis; H G Watson; F McOmish; J F Peutherer; C A Ludlam; P Simmonds
Journal:  J Infect Dis       Date:  1994-10       Impact factor: 5.226

8.  Sequence variability in the 5' non-coding region of hepatitis C virus: identification of a new virus type and restrictions on sequence diversity.

Authors:  P Simmonds; F McOmish; P L Yap; S W Chan; C K Lin; G Dusheiko; A A Saeed; E C Holmes
Journal:  J Gen Virol       Date:  1993-04       Impact factor: 3.891

9.  Analysis of a new hepatitis C virus type and its phylogenetic relationship to existing variants.

Authors:  S W Chan; F McOmish; E C Holmes; B Dow; J F Peutherer; E Follett; P L Yap; P Simmonds
Journal:  J Gen Virol       Date:  1992-05       Impact factor: 3.891

10.  Detection of three types of hepatitis C virus in blood donors: investigation of type-specific differences in serologic reactivity and rate of alanine aminotransferase abnormalities.

Authors:  F McOmish; S W Chan; B C Dow; J Gillon; W D Frame; R J Crawford; P L Yap; E A Follett; P Simmonds
Journal:  Transfusion       Date:  1993-01       Impact factor: 3.157

View more
  8 in total

1.  Characterization of a panel of monoclonal antibodies and mapping the epitopes of hepatitis C virus proteins.

Authors:  O V Masalova; A G Abdulmedzhidova; S N Atanadze; E I Lakina; YuA Semiletov; A N Burkov; T I Ulanova; V V Novikov; V K Pimenov; G Filds; YuE Khudyakov; A A Kushch
Journal:  Dokl Biochem Biophys       Date:  2002 Mar-Apr       Impact factor: 0.788

2.  Definition of false-positive reactions in screening for hepatitis C virus antibodies.

Authors:  M Schröter; H H Feucht; P Schäfer; B Zöllner; S Polywka; R Laufs
Journal:  J Clin Microbiol       Date:  1999-01       Impact factor: 5.948

3.  Screening for hepatitis C virus infection in a high prevalence country by an antigen/antibody combination assay versus a rapid test.

Authors:  Claude Tayou Tagny; Dora Mbanya; Edward L Murphy; Jean-Jacques Lefrère; Syria Laperche
Journal:  J Virol Methods       Date:  2014-01-30       Impact factor: 2.014

4.  Detection of antibodies to hepatitis C virus in dried blood spot samples from mothers and their offspring in Lahore, Pakistan.

Authors:  S P Parker; H I Khan; W D Cubitt
Journal:  J Clin Microbiol       Date:  1999-06       Impact factor: 5.948

5.  HCV-specific CD27- CD28- memory T cells are depleted in hepatitis C virus and Schistosoma mansoni co-infection.

Authors:  Mohamed Elrefaei; Nabila El-Sheikh; Karim Kamal; Huyen Cao
Journal:  Immunology       Date:  2003-12       Impact factor: 7.397

6.  HCV and GBV-c/HGV infection in HIV positive patients in southern Italy.

Authors:  D Rendina; E Vigorita; R Bonavolta; M D'Onofrio; A Iura; M T Pietronigro; R Laccetti; G Bonadies; G Liuzzi; G Borgia; P Formisano; P Laccetti; G Portella
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

7.  Interferon alpha plus ribavirin combination treatment of Japanese chronic hepatitis C patients with HCV genotype 2: a project of the Kyushu University Liver Disease Study Group.

Authors:  Norihiro Furusyo; Masaki Katoh; Yuichi Tanabe; Eiji Kajiwara; Toshihiro Maruyama; Junya Shimono; Hironori Sakai; Makoto Nakamuta; Hideyuki Nomura; Akihide Masumoto; Shinji Shimoda; Kazuhiro Takahashi; Koichi Azuma; Jun Hayashi
Journal:  World J Gastroenterol       Date:  2006-02-07       Impact factor: 5.742

8.  Antigenic heterogeneity of the hepatitis C virus NS5A protein.

Authors:  Xiao-Guang Dou; Ganesh Talekar; Joy Chang; Xing Dai; Lixia Li; Maria-Teresa Bonafonte; Brian Holloway; Howard A Fields; Yury E Khudyakov
Journal:  J Clin Microbiol       Date:  2002-01       Impact factor: 5.948

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.